Top

Osteoporosis International

Published in:

01-06-2018 | Concise Clinical Review

A proposal for an atypical femur fracture treatment and prevention clinical practice guideline

Authors: R. Dell, D. Greene

Published in: Osteoporosis International | Issue 6/2018

Abstract

Summary

The prevention as well as the treatment of atypical femur fractures (AFFs) remains controversial but there have been many clinical recommendations suggested. We have summarized these recommendations as well as expanded upon them in this paper.

Introduction

The purpose of the paper was to develop a clinical practice guideline that both treats AFF and decreases the risk of AFF in patients requiring antiresorptive medications. Examples of these medications include bisphosphonates and denosumab for the treatment of osteoporosis.

Methods

A literature review looking for recommendations on AFF identification, management, and prevention was done. We also performed an updated review of clinical guidelines on AFF prevention and treatment that were developed for the Kaiser Permanente osteoporosis/fracture prevention team.

Results

Concise clinical practice guidelines are presented that can be applied in treatment of AFF as well as help reduce the risk of developing an AFF in patients requiring antiresorptive medications. These guidelines are based on using both typical fracture and AFF risk assessment to determine duration of antiresorptive of 3 to 5 years before consideration if a drug holiday is needed. Specific groups such as younger Asian women should be reassessed at 3 years with DXA and FRAX to see if a drug holiday is needed whereas patients at higher risk for typical fractures may be reassessed at 5 years of treatment. The DXA rescreening can now be accessed if focal or generalized lateral cortex changes are present that may indicate incomplete AFFs are present. If an incomplete AFF is discovered either by DXA or by other imaging studies, it is imperative to stop antiresorptive medications and to take additional measures to lower the risk of progression to a complete AFF. If complete AFF does occur, then antiresorptive medications should be stopped and additional measures should be taken to decrease the risk of developing an AFF on the contralateral femur.

Conclusions

Clinical practice guidelines for the treatment and prevention of AFF will benefit clinicians who are frequently faced with having to make clinical decisions in patients requiring antiresorptive medications.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed

Goh SK, Yang KY, Koh JSB et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br (3):349–353

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, Fracture Intervention Trial Steering Committee., HORIZON Pivotal Fracture Trial Steering Committee (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362(19):1761–1771CrossRefPubMed

Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102CrossRefPubMed

Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016 Jan) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35CrossRefPubMedPubMedCentral

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014 Jan) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23CrossRefPubMed

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 25(10):2359–2381CrossRef

Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012 Dec) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550CrossRefPubMed

Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B (2016 Apr) The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85:142–147CrossRefPubMedPubMedCentral

10.

Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, Gonzalez JR, Hui RL, Grimsrud CD (2012 Jul) Clinical correlates of atypical femoral fracture. Bone 51(1):181–184CrossRefPubMed

11.

Dell RM, Greene D, Tran D. Stopping bisphosphonate treatment decreases the risk of having a second atypical femoral fracture. Paper presented at: American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting 2012 Feb 7–11; San Francisco, CA, USA

12.

Koh JS, Goh SK, Png MA, Ng AC, Howe TS (2011 Feb) Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singap Med J 52(2):77–80

13.

Taormina DP, Marcano AI, Karia R, Egol KA, Tejwani NC (2014 Jun) Symptomatic atypical femoral fractures are related to underlying hip geometry. Bone 63:1–6CrossRefPubMed

14.

Ng AC, Png MA, Chua DT, Koh JS, Howe TS (2014) Review: epidemiology and pathophysiology of atypical femur fractures. Curr Osteoporos Rep 12(1):65–73CrossRefPubMed

15.

Jang SP, Yeo I, So SY, Kim K, Moon YW, Park YS, Lim SJ (2017) Atypical femoral shaft fractures in female bisphosphonate users were associated with an increased anterolateral femoral bow and a thicker lateral cortex: a case-control study. Biomed Res Int 2017:5932496CrossRefPubMedPubMedCentral

16.

Oh Y, Wakabayashi Y, Kurosa Y, Ishizuki M, Okawa A (2014) Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly Japanese: a case series. J Orthop Sci 19(4):579–586CrossRefPubMed

17.

Hagen JE, Miller AN, Ott SM, Gardner M, Morshed S, Jeray K, Alton TB, Ren D, Abblitt WP, Krieg JC (2014) Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. J Bone Joint Surg Am 96(22):1905–1909CrossRefPubMed

18.

Pérez-Núñez I, Pérez-Castrillón JL, Zarrabeitia MT, García-Ibarbia C, Martínez-Calvo L, Olmos JM, Briongos LS, Riancho J, Camarero V, Muñoz Vives JM, Cruz R, Riancho JA (2015) Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. Mol Cell Biochem 409(1–2):45–50CrossRefPubMed

19.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRefPubMed

20.

McKenna MJ, van der Kamp S, Heffernan E, Hurson C (2013) Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by extending femur length. J Clin Densitom 16(4):579–583CrossRefPubMed

21.

Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737CrossRefPubMed

22.

Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R (2015) Atypical femur fracture during bisphosphonate drug holiday: a case series. Osteoporos Int 26(6):1755–1758CrossRefPubMed

23.

Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30CrossRefPubMed

24.

Anagnostis P, Stevenson JC (2015) Bisphosphonate drug holidays—when, why and for how long? Climacteric 18(Suppl 2):32–38CrossRefPubMed

25.

Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis–executive summary. Arch of Osteoporos 7:3–20CrossRef

26.

Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, Nagao M, Sakamoto Y, Sakai K, Homma Y, Kato R, Nagura N, Miyagawa K, Wada T, Liu L, Matsuoka J, Obayashi O, Shitoto K, Nozawa M, Kajihara H, Gen H, Kaneko K (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33(3):311–318CrossRefPubMed

27.

Png M, Koh J, Goh S, Fook-Chong S, Howe T (2012) Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. Am J Roentgenol 198:869–877CrossRef

28.

Min BW, Koo KH, Park YS, Oh CW, Lim SJ, Kim JW, Lee KJ, Lee YK (2017 Feb 1) Scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. J Clin Endocrinol Metab 102(2):545–550PubMed

29.

Im GI, Lee SH (2015) Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 22(4):183–189CrossRefPubMedPubMedCentral

30.

Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM (2012 Jul) Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J 8(2):103–110CrossRefPubMedPubMedCentral

31.

Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96:1627–1632CrossRefPubMed

32.

Koh JS, Goh SK, Png MA et al (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24(2):75–81CrossRefPubMed

33.

Donnelly E, Saleh A, Unnanuntana A, Lane JM (2012) Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care 6(3):348–354CrossRefPubMedPubMedCentral

34.

Watts NB, Aggers D, McCarthy EF et al (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. Bone Miner Res 32(5):1027–1033CrossRef

35.

Koh A, Guerado E, Giannoudis PV (2017) Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J 99-B(3):295–302CrossRefPubMed

36.

Park YC, Song HK, Zheng XL, Yang KH (2017 May 3) Intramedullary nailing for atypical femoral fracture with excessive anterolateral bowing. J Bone Joint Surg Am 99(9):726–735CrossRefPubMed

37.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed

38.

Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–190CrossRefPubMed

39.

Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC (2014) Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res 472(9):2728–2734CrossRefPubMed

40.

Gustafsson A, Schilcher J, Grassi L, Aspenberg P, Isaksson H (2016) Strains caused by daily loading might be responsible for delayed healing of an incomplete atypical femoral fracture. Bone 88:125–130CrossRefPubMed

41.

Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2016) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res:29. https://doi.org/10.1002/jbmr.3074

Title: A proposal for an atypical femur fracture treatment and prevention clinical practice guideline
Authors: R. Dell
D. Greene
Publication date: 01-06-2018
Publisher: Springer London
Published in: Osteoporosis International / Issue 6/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-018-4506-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A proposal for an atypical femur fracture treatment and prevention clinical practice guideline

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Effects of bone remodeling agents following teriparatide treatment

Correction to: Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes

The role of previous falls in major osteoporotic fracture prediction in conjunction with FRAX in older Chinese men and women: the Mr. OS and Ms. OS cohort study in Hong Kong

Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients

Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study

Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis